30th week of 2010 patent applcation highlights part 47 |
Patent application number | Title | Published |
20100190741 | INJECTABLE CROSS-LINKED POLYMERIC PREPARATIONS AND USES THEREOF - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue. | 2010-07-29 |
20100190742 | COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISING HYALURONIC ACID AND ADMINISTRATION THEREOF FOR REDUCING SIGNS OF AGING - Cosmetic/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, at least (i) hyaluronic acid and/or one of its derivatives and (ii) a C-glycoside compound, at least one of the constituents (i) and (ii) advantageously being in a form suitable for administration by injection, and administration thereof for filling depressions on the surface of the skin and for reducing signs of aging or for re-establishing the volume of the body or face. | 2010-07-29 |
20100190743 | Method and Composition for Treatment of a Mucosal Tissue Disorder - Methods of treating a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis, by administering a medicament containing a sulfated chitinous polymer administered topically are described. Pharmaceutical compositions containing the sulfate chitinous polymer are also disclosed. | 2010-07-29 |
20100190744 | COMPOSITIONS AND METHODS OF TREATING VIRAL INFECTIONS - The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, | 2010-07-29 |
20100190745 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF - Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. | 2010-07-29 |
20100190746 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions. | 2010-07-29 |
20100190747 | Fused ring compound and use thereof - The present invention provides a compound represented by the formula: | 2010-07-29 |
20100190748 | BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. | 2010-07-29 |
20100190749 | Benzoxazole kinase inhibitors and methods of use - The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications. | 2010-07-29 |
20100190750 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto - The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual. | 2010-07-29 |
20100190751 | NOVEL COMBINATION OF NERAMEXANE FOR TREATMENT OF NERORDEGENERATIE DISORDERS - The present invention relates to combinations comprising neramexane and a Glutamate Release Inhibitor (GRI) and the use of such combinations in the treatment of neurodegenerative disorders. | 2010-07-29 |
20100190752 | Pharmaceutical Combination - A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 2010-07-29 |
20100190753 | Methods and Compositions for Treating Amyloid-Related Diseases - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease. | 2010-07-29 |
20100190754 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF - An azolylmethylidenehydrazine derivative represented by the formula (I) | 2010-07-29 |
20100190755 | TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT - The present invention pertains, at least in part, to substituted tetracycline compounds. The present invention also pertains to methods for treating rheumatoid arthritis in a subject, comprising administering to the subject a tetracycline compound of the invention. | 2010-07-29 |
20100190756 | 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2010-07-29 |
20100190757 | COMBINATION PREPARATION FOR ORAL CONTREACEPTION AND ORAL THERAPY OF DYSFUNCTIONAL UTERINE BLEEDING CONTAINING ESTRADIOL VALERATE AND DIENOGEST AND METHOD OF USING SAME - The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos. | 2010-07-29 |
20100190758 | Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding - Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days. | 2010-07-29 |
20100190759 | NK 1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 2010-07-29 |
20100190760 | Process for Making Crystals - A process for preparing an emulsion or a dispersion comprising crystalline particles of at least one active principal that comprises contacting a solution of at least one solute in a solvent or mixture of solvents in a first flowing stream with a non-solvent in a second flowing stream wherein the non-solvent and solvent are not miscible with each other, so as to form an emulsion or a dispersion. Super saturation is brought about by suitable means, and the emulsion or dispersion is subjected to ultrasonic irradiation to mediate crystal nucleation. | 2010-07-29 |
20100190761 | DIPHENYL SUBSTITUTED ALKANES - The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents. | 2010-07-29 |
20100190762 | TRIAZOLYL PHENYL BENZENESULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists. | 2010-07-29 |
20100190763 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors - Disclosed are compounds of the following formula: | 2010-07-29 |
20100190764 | Novel compounds - This invention relates to novel Spiro cyclopentane derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders. | 2010-07-29 |
20100190765 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2010-07-29 |
20100190766 | ANTIBACTERIAL AGENTS - Antibacterial compounds of formula (I) are provided: | 2010-07-29 |
20100190767 | Compounds for the treatment of inflammatory diseases - Compounds of formula 1 and hetero derivatives thereof | 2010-07-29 |
20100190768 | NOVEL FUSED PYROLE DERIVATIVE - The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: | 2010-07-29 |
20100190769 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE - Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R | 2010-07-29 |
20100190770 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. | 2010-07-29 |
20100190771 | AMINO-HETEROCYCLIC COMPOUNDS - The invention provides PDE9-inhibiting compounds of Formula (I), | 2010-07-29 |
20100190772 | Substituted Azepine Derivatives As Serotonin Receptor Modulators - The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | 2010-07-29 |
20100190773 | Anti-Cytokine Heterocyclic Compounds - Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors. | 2010-07-29 |
20100190774 | INHIBITORS OF C-MET AND USES THEREOF - The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders. | 2010-07-29 |
20100190775 | PYRIMIDODIAZEPINONE DERIVATIVE - The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) | 2010-07-29 |
20100190776 | Thiazoline and Oxazoline Derivatives and Their Methods of Use - The invention relates to a series of thiazoline and oxazoline derivatives, compositions thereof, and methods of treating conditions and disorders using such compounds. | 2010-07-29 |
20100190777 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R | 2010-07-29 |
20100190778 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE - The present invention is related to new 3,4-dihydroberizo[1,2,3]thiadiazine-1,1-dioxide derivatives of the Formula (I), medicaments containing said new compounds, process for the preparation thereof and the use of said derivatives in the medicine. The compounds according to the present invention are suitable for the treatment or prevention of disorders of the central nervous system. | 2010-07-29 |
20100190779 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 2010-07-29 |
20100190780 | SIGMA RECEPTOR INHIBITORS - The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved. | 2010-07-29 |
20100190781 | SIGMA RECEPTOR INHIBITORS - The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved. | 2010-07-29 |
20100190782 | COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 2010-07-29 |
20100190783 | TRIAZOLONE DERIVATIVES - A Compound represented by the following general formula (1): | 2010-07-29 |
20100190784 | Organic Compounds - A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, | 2010-07-29 |
20100190785 | METHOD FOR THE PURIFICATION OF MYCOPHENOLATE MOFETIL - The present invention provides a method for the preparation of mycophenolate mofetil wherein mycophenolic acid or an amine salt of mycophenolic acid is esterified with 2-morpholinoethanol, the resulting mixture is extracted into water at a pH-value between 1.0 and 3.0, and mycophenolate mofetil is back-extracted in a water-immiscible solvent at a pH-value between 3.0 and 5.0. | 2010-07-29 |
20100190786 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES - The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to certain indolin-2-ones and aza-indolin-2-ones which possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body, in particular such compounds are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis. | 2010-07-29 |
20100190787 | Modulators of Mitotic Kinases - The invention relates to compounds of Formula (I), a prodrug, a polymorph, a tautomer, an enantiomer, a stereoisomer, a solvate, an N-oxide, or a pharmaceutically acceptable salt thereof: (formula should be inserted here) which have inhibitory effect on one or more protein kinases that are involved in cell mitosis. | 2010-07-29 |
20100190788 | Amide derivatives as kinase inhitors - The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar | 2010-07-29 |
20100190789 | PIPERIDINE/PIPERAZINE DERIVATIVES - The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NR | 2010-07-29 |
20100190790 | SIGMA RECEPTOR INHIBITORS - The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved. | 2010-07-29 |
20100190791 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners - The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer. | 2010-07-29 |
20100190792 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds (I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII). | 2010-07-29 |
20100190793 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS - Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity. | 2010-07-29 |
20100190794 | Herbicidally Active Composition - The present invention relates to herbicidally active compositions comprising at least one piperazinedione compound of the formula I | 2010-07-29 |
20100190795 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS - The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus | 2010-07-29 |
20100190796 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS - Provided herein are methods for identifying and characterizing agents that alter the volume of a cell. Methods are provided for rapid screening and identification of an agent that alters the capability of a small, neutrally charged solute transporter to transport the solute across a cell membrane. The methods described herein may be used to identify and characterize inhibitors of urea transporters, to identify and characterize inhibitors of aquaporins, and to identify and characterize inhibitors of other small, neutrally charged solutes such as glucose. | 2010-07-29 |
20100190797 | CRYSTALLINE POLYMOPHIC FORMS OF ZOPICLONE, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS - Disclosed are processes for the preparation of crystalline polymorphic forms of zopiclone and their pharmaceutical compositions for use as a sedative. | 2010-07-29 |
20100190798 | PHARMACEUTICAL COMPOSITION COMPRISING RACEMIC AMINOPTERIN - There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof. | 2010-07-29 |
20100190799 | PHENAZINE COMPOUNDS AND USE THEREOF IN AUTOIMMUNE AND INFLAMMATORY DISEASES - The invention discloses compounds, compositions and methods useful for preventing and/or treating autoimmune diseases and inflammatory diseases. The methods and compositions utilize water-soluble phenazine compounds, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent autoimmune diseases and inflammatory diseases such as those caused by arthritis and rheumatoid arthritis. | 2010-07-29 |
20100190800 | COMBINATON OF PYRIMIDYLAMINOBENZAMIDE COMPOUNDS AND IMATINIB FOR TREATING OR PREVENTING PROLIFERATIVE DISEASES - The invention provides a pharmaceutical combination comprising:
| 2010-07-29 |
20100190801 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments. | 2010-07-29 |
20100190802 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME - Disclosed are carboxamide compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 2010-07-29 |
20100190803 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT - Disclosed are bis(styryl)pyrimidine or bis(styryl)benzene compounds, represented by Chemical Formula 1, pharmaceutically acceptable salts, a method for preparing the same, and a pharmaceutical composition for the prevention and treatment of amyloidosis-associated diseases, comprising the same as an active ingredient. Having the ability to inhibit the deposition of beta amyloid and to reduce the toxicity of beta amyloid, the derivatives can improve learning and memory and can be useful in the prevention and treatment of amyloidosis-associated diseases. | 2010-07-29 |
20100190804 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS - The present invention relates to macrocyclic compounds of Formula I: | 2010-07-29 |
20100190805 | PREPARATION FOR THE TREATMENT OF EQUINE LAMINITIS - Disclosed is the use of active substances known from human medicine for treating gout in order to pharmaceutically treat equine laminitis, especially the use of a preparation containing at least allopurinol and/or hydrocortisone and/or powdered opium and/or prednisolone and/or prednisone. | 2010-07-29 |
20100190806 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES - The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives. | 2010-07-29 |
20100190807 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein - The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting increases in MAPT expression induced by the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. | 2010-07-29 |
20100190808 | Tricyclic Compounds As Modulators of TNF-alpha Synthesis - The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis. | 2010-07-29 |
20100190809 | COMBINATION FORMULATIONS - This invention relates to solid oral dosage forms of the HIV inhibitors containing a combination of TMC114 and TMC125. | 2010-07-29 |
20100190810 | COMPOSITION AND METHOD FOR TREATMENT OF WARTS - Provided is a composition comprising 5-FU and salicylic acid. This composition is useful as a treatment for warts. As opposed to conventional compositions and methods, this composition need only be applied once a day. Also provided are methods for the preparation and use of the composition for treatment of warts. | 2010-07-29 |
20100190811 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS - The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. | 2010-07-29 |
20100190812 | NILOTINIB HCL CRYSTALLINE FORMS - Crystalline forms of Nilotinib HCl are described. | 2010-07-29 |
20100190813 | SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS - The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some thieno-pyrano-pyrazole derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis or pain. | 2010-07-29 |
20100190814 | SPIROINDOLINONE DERIVATIVE PRODRUGS - There are provided compounds of the formula | 2010-07-29 |
20100190815 | HYPERTENSION-AMELIORATING AGENT - It is an objective of the present invention to provide a safe and highly effective hypertension-ameliorating agent. | 2010-07-29 |
20100190816 | KINASE INHIBITORS - Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: | 2010-07-29 |
20100190818 | Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives - The invention relates to salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical composition for use, e.g., in treatment of airway disorders. | 2010-07-29 |
20100190819 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof - The present application is related to compounds represented by Formula I, which are novel allosteric modulators of α7nAChR. The application also discloses the treatment of disorders that are responsive to modulation of acetylcholine action on α7nAChR in a mammal by administering an effective amount of a compound of Formula I. | 2010-07-29 |
20100190820 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (R | 2010-07-29 |
20100190821 | 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2010-07-29 |
20100190822 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) - The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. | 2010-07-29 |
20100190823 | Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds - Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed. | 2010-07-29 |
20100190824 | Novel Substituted Piperidones as HSP Inducers - The present invention relates to novel compounds of formula (I) or (II), their pharmaceutically acceptable salts and their hydrates, solvates, stereoisomers, conformers, tautomers, polymorphs and prodrugs and also pharmaceutically acceptable compositions containing them Wherein R | 2010-07-29 |
20100190825 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I) and salts and solvates are provided: | 2010-07-29 |
20100190826 | BENZIMIDAZOLE DERIVATIVE - Provided is a novel and excellent method for treating and/or preventing benign prostatic hyperplasia, prostate cancer, and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an indole or benzimidazole derivative, where a nitrogen atom of the indole ring or benzimidazole ring is substituted with a phenyl group substituted with COOH, has a potent selective inhibitory activity against 17βHSD type 5 and may become an agent for treating and/or an agent for preventing a disease associated with 17βHSD type 5, such as benign prostatic hyperplasia, prostate cancer and the like, without accompanying adverse effects due to a decrease in testosterone; and the present invention has thus been completed. | 2010-07-29 |
20100190827 | POLYMORPHIC FORM OF RIMONABANT, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - The present invention relates to a novel crystalline polymorph of rimonabant, its method of preparation and the pharmaceutical compositions containing this novel polymorph. | 2010-07-29 |
20100190828 | Thiazolyl oxime ethers and hydrazones as crop protection agents - Thiazolyl oxime ethers and hydrazones of the formula (I), | 2010-07-29 |
20100190829 | RENIN INHIBITORS - Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. | 2010-07-29 |
20100190830 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives - The present invention relates to (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives of Formula (I) wherein R | 2010-07-29 |
20100190831 | GPR120 RECEPTOR AGONISTS AND USES THEREOF - GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control. | 2010-07-29 |
20100190832 | Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates - Transthyretin (TTR), a tetrameric thyroxine (T4) carrier protein, is associated with a variety of amyloid diseases. Derivative of biphenyl ethers (BPE), which are shown to interact with a high affinity to its T4 binding site thereby preventing its aggregation and fibrillogenesis. They prevent fibrillogenesis by stabilizing the tetrameric ground state of transthyretin. Two compounds (2-(5-mercapto-[1,3,4]oxadiazol-2-yl)-phenol and 2,3,6-trichloro-N-(4H-[1,2,4]triazol-3-yl) exhibit the ability to arrest TTR amyloidosis. The dissociation constants for the binding of BPEs and compound 11 and 12 to TTR correlate with their efficacies of inhibiting amyloidosis. They also have the ability to inhibit the elongation of intermediate fibrils as well as show nearly complete (>90%) disruption of the preformed fibrils. Biphenyl ethers and compounds 11 and 12 as very potent inhibitors of TTR fibrillization and inducible cytotoxicity. | 2010-07-29 |
20100190833 | PHARMACEUTICAL CONTAINING PPARA AGONIST - Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. | 2010-07-29 |
20100190834 | COMPOSITION FOR OPHTALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA - According to the present invention, a composition containing a VAP-1 inhibitor as an active ingredient, which is effective for ophthalmic diseases associated with hypoxia or ischemia can be provided. According to the present invention, moreover, an angiogenesis inhibitor that suppresses pathologic angiogenesis associated with hypoxia or ischemia can be provided. | 2010-07-29 |
20100190835 | PHARMACEUTICAL COMPOSITION COMPRISING ALEGLITAZAR - The invention relates to a pharmaceutical composition comprising aleglitazar and to the process of manufacture and uses thereof. | 2010-07-29 |
20100190836 | Compounds, Screens, and Methods of Treatment - The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described. | 2010-07-29 |
20100190837 | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom - The present invention provides 5′-substituted-2′-F nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In one preferred embodiment the nucleoside analogs have either (R) or (5)-chirality at the 5′-position. These nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance. | 2010-07-29 |
20100190838 | Connective Tissue Growth Factor Fragments and Methods and Uses Thereof - The present invention is directed to CTGF fragments comprising at least exon 2 or exon 3 of CTGF and having the ability to induce extracellular matrix synthesis, in particular, collagen synthesis and myofibroblast differentiation. The present invention is further directed to methods using said CTGF fragments to identify compositions which modulate the activity of said CTGF fragments and to the compositions so identified. The invention also relates to methods of treating CTGF-associated disorders and diseases associated with the overproduction of the extracellular matrix. | 2010-07-29 |
20100190839 | Telomere-Encoding Synthetic DNA Nanocircles, and Their Use for the Elongation of Telomere Repeats - Telomere-encoding nucleic acid nanocircles, methods for their preparation, and methods for their use are disclosed. The nanocircles can be constructed containing multiple repeats of the complement of telomere repeat sequences. The telomere-encoding nanocircles are useful for extending telomeres both in vitro and in vivo, for treating macular degeneration, the effects of skin aging, liver degeneration, and cancer. The nanocircles are further useful for treating cell cultures to produce long-lived non-cancerous cell populations. This use has wide applicability in scientific research, tissue engineering, and transplantation. | 2010-07-29 |
20100190840 | TISSUE SPECIFIC GENE THERAPY TREATMENT - The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca | 2010-07-29 |
20100190841 | GENETIC SUPPRESSION AND REPLACEMENT - The invention relates to gene suppression and replacement. In particular, the invention relates to enhanced expression of suppression agents for suppressing gene expression in a cell and in vivo and replacement nucleic acids that are not inhibited by the suppression agent. Regulatory elements are included in expression vectors to optimize expression of the suppression agent and/or replacement nucleic acid. | 2010-07-29 |